Review of Trends, Variation and Outcomes in Impella® Use Dr. Seth Bilazarian, Abiomed’s Chief Medical Officer, provides a review of the observational analysis published in Circulation and presented at AHA 2019 by Amin, et al., comparing Impella to IABP. Dr. Bilazarian notes that the study is an observational, non-FDA audited analysis that is fundamentally flawed … Continue reading “Publication Review: Amin Analysis on Impella and IABP”
What is Cardiogenic Shock? Cardiogenic shock is a life-threatening condition that occurs when the heart can no longer pump enough blood to the body, usually as a result of an acute myocardial infarction. The goals of cardiogenic shock treatment are to restore blood flow and protect organs from damage. The Impella® heart pump provides hemodynamic … Continue reading “Top Cardiogenic Shock Treatment Objectives and Device Options”
Acute Ventricular Unloading and Cardioprotection During MI Jerry Curran PhD, Senior Scientist at Abiomed, discusses a paper he recently co-authored describing how acute ventricular unloading is fundamentally different from other clinical therapies for attenuating the impact of ischemic-reperfusion (I-R) injury in the setting of myocardial infarction. The paper, co-authored with Dr. Daniel Burkhoff and Dr. … Continue reading “Clinical Paper: Beyond Reperfusion by Jerry Curran”
Reference: J Interven Cardiol 2016; 29:248–256. Cardiogenic shock (CS) is the leading cause of death after acute myocardial infarction (AMI) and occurs in up to 10% of cases.1 Notably, the incidence of CS is higher in women presenting with STEMI than men (11.6% vs. 8.3%, p < 0.01).2 Previous studies evaluating the impact of CS … Continue reading “Impella Support Pre-PCI for AMICS is Associated with Higher Survival in Women”
Reference: J Am Coll Cardiol 2018; 72:1972-80 Cardiogenic shock continues to be the leading cause of death in patients with acute myocardial infarction (AMI).1 Despite implementation of guideline-recommended early revascularization, mortality rates in AMI complicated by cardiogenic shock (AMICS) remains constant at about 50%. Given that about 60,000 patients with AMI develop CS every year,2 … Continue reading “Improving Survival in Cardiogenic Shock by Adopting a Uniform Approach to Systems of Care”
- This meta-analysis evaluated 6 randomized controlled trials to determine outcome differences between percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) among patients with unprotected left main coronary artery disease ([ULMCAD] n = 4686).
- Compared with CABG, PCI correlated with significantly lower rates of 30-day stroke (P = 0.007), death or MI (P = 0.04), or all-cause death, MI, or stroke (P = 0.01).
- In the PCI group, there was a significantly lower rate of 30-day stroke incidence (P = 0.007) and all-cause death, MI, or stroke (P = 0.01).
- The authors found no significant difference in outcomes at long-term follow-up (median 39 months) between the two groups.
Key Takeaways Patients with cardiogenic shock (CS) due to end-stage heart failure (ESHF) who receive mechanical circulatory support (MSC) have lower global oxygen delivery, greater anaerobic metabolism, lower pulmonary capacitance, and higher pulmonary vascular resistance than patients with CS due to acute myocardial infraction (AMI). Table 1. Types of Supporta Primary Support (n, %) CS … Continue reading “Characteristics of Cardiogenic Shock Subtypes for Guiding Clinical Practice”
Reference: Ait Ichou J et al. Catheter Cardiovasc Interv [published online September 20, 2017]. Key Takeaways Hemodynamic support with the Impella® device is associated with low mortality and low adverse events in patients undergoing high-risk percutaneous coronary intervention (HRPCI), according to a systematic review. According to findings from a systematic review by Ichou et al, … Continue reading “Safety and Feasibility of the Impella® Device in High-Risk Percutaneous Coronary Intervention”
Reference: Escaned J et al. Eur Heart J. 2017;38(42):3124-3134. Patients selected for percutaneous coronary intervention (PCI) using the Syntax Score II in the SYNTAX II trial showed favorable 1-year post-intervention clinical outcomes compared to patients selected for PCI in the SYNTAX I trial, according to findings from the SYNTAX II trial.1 SYNTAX II The SYNTAX … Continue reading “Utility of the SYNTAX II Score for Deciding Between PCI and CABG”
Impella® Device Support During High-Risk Unprotected Left Main Percutaneous Coronary Intervention Demonstrates Favorable Safety and Efficacy Outcomes
Reference: Schreiber T et al. Catheter Cardiovasc Interv. 2017;90(4):576-581. The use of prophylactic Impella® device support during unprotected left main (ULM) percutaneous coronary intervention (PCI) is safe and effective for improving hemodynamic variables in high-risk, non-cardiogenic shock (CS) patients, according to findings from a large, single-center, retrospective review of the USpella registry from Schreiber et … Continue reading “Impella® Device Support During High-Risk Unprotected Left Main Percutaneous Coronary Intervention Demonstrates Favorable Safety and Efficacy Outcomes”